Table 4.
The relationship of IRIS occurrence and initiation timing of HAART among HIV-TB co-infected patients*
| Total (n = 182) | IRIS (N = 57, 25%) | Hazard ratio (95% CI) | Adjusted HR # (95% CI) | Adjusted HR $ (95% CI) | |
|---|---|---|---|---|---|
| Age at TB diagnosis (per 5-year increase) |
|
|
0.99 (0.97-1.01) |
0.99 (0.97-1.02) |
0.99 (0.97-1.02) |
| CD4 count at TB diagnosis (per 50-cell increase) |
|
|
0.95 (0.81-1.11) |
0.97 (0.83-1.13) |
0.97 (0.83-1.13) |
| HAART initiation timing during anti-TB therapy | |||||
| 0–15 days |
110 |
41 (71.9%) |
1 |
1 |
4.24 (1.02-19.5) |
| 16–30 days |
34 |
12 (21.1%) |
0.98 (0.51-1.86) |
0.96 (0.50-1.84) |
4.08 (0.91-18.3) |
| 31–60 days |
19 |
2 (3.5%) |
0.23 (0.06-0.96) |
0.24 (0.06-0.98) |
1 |
| >60 days | 19 | 2 (3.5%) | 0.26 (0.06-1.06) | 0.27 (0.07-1.12) | 1.14 (0.16-8.11) |
Abbreviations:HAART highly active antiretroviral therapy, IRIS Immune reconstitution inflammatory syndrome.
*Only enrolled cases with available CD4+ lymphocyte count and start HAART during TB treatment. HBV co-infection, HCV co-infection and TB location were analyzed initially but the p-value was greater than 0.15 and was not included for multivariate analysis and not shown in the table.
#Adjusted for age at TB diagnosis, CD4+ lymphocyte count and HAART initiation timing (use initiation timing at 0–15 days as reference).
$Adjusted for age at TB diagnosis, CD4+ lymphocyte count and HAART initiation timing (use initiation timing at 31–60 days as reference).